Meeting: FDA and HHS Peripheral and Central Nervous System Drugs Advisory Committee

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues.The committee will discuss new drug application (NDA) 210365, cannabidiol oral solution, sponsored by GW Pharmaceuticals, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. FDA intends to make background material available to the public no later than 2 business days before the meeting. 

Meeting location and contact information is available via the Federal Register notice. A correction to the docket number provided for this meeting is available here.

Event Date
Thursday, April 19, 2018 -
8:00am to 12:30pm
Topics
Neuroscience